406 related articles for article (PubMed ID: 16384937)
1. HLA Class I and II genotype in uveal melanoma: relation to occurrence and prognosis.
Maat W; Haasnoot GW; Claas FH; Schalij-Delfos NE; Schreuder GM; Jager MJ
Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):3-6. PubMed ID: 16384937
[TBL] [Abstract][Full Text] [Related]
2. Normal HLA class I, II, and MICA gene distribution in uveal melanoma.
Metzelaar-Blok JA; Hurks HM; Naipal A; De Lange P; Keunen JE; Claas FH; Doxiadis II; Jager MJ
Mol Vis; 2005 Dec; 11():1166-72. PubMed ID: 16379028
[TBL] [Abstract][Full Text] [Related]
3. A comparison of HLA genotype with inflammation in uveal melanoma.
van Essen TH; Bronkhorst IH; Maat W; Verduyn W; Roelen DL; Luyten GP; Jager MJ
Invest Ophthalmol Vis Sci; 2012 May; 53(6):2640-6. PubMed ID: 22447860
[TBL] [Abstract][Full Text] [Related]
4. Association of HLA class I and class II antigen expression and mortality in uveal melanoma.
Ericsson C; Seregard S; Bartolazzi A; Levitskaya E; Ferrone S; Kiessling R; Larsson O
Invest Ophthalmol Vis Sci; 2001 Sep; 42(10):2153-6. PubMed ID: 11527924
[TBL] [Abstract][Full Text] [Related]
5. Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma.
Maat W; Ly LV; Jordanova ES; de Wolff-Rouendaal D; Schalij-Delfos NE; Jager MJ
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):505-10. PubMed ID: 18234992
[TBL] [Abstract][Full Text] [Related]
6. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma.
Blom DJ; Luyten GP; Mooy C; Kerkvliet S; Zwinderman AH; Jager MJ
Invest Ophthalmol Vis Sci; 1997 Aug; 38(9):1865-72. PubMed ID: 9286277
[TBL] [Abstract][Full Text] [Related]
7. Evidence for natural killer cell-mediated protection from metastasis formation in uveal melanoma patients.
Maat W; van der Slik AR; Verhoeven DH; Alizadeh BZ; Ly LV; Verduijn W; Luyten GP; Mulder A; van Hall T; Koning F; Jager MJ; van Bergen J
Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2888-95. PubMed ID: 19234348
[TBL] [Abstract][Full Text] [Related]
8. Cytogenetics of uveal melanoma: a 7-year clinical experience.
Damato B; Duke C; Coupland SE; Hiscott P; Smith PA; Campbell I; Douglas A; Howard P
Ophthalmology; 2007 Oct; 114(10):1925-31. PubMed ID: 17719643
[TBL] [Abstract][Full Text] [Related]
9. MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells.
Bosch JJ; Thompson JA; Srivastava MK; Iheagwara UK; Murray TG; Lotem M; Ksander BR; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4499-506. PubMed ID: 17483366
[TBL] [Abstract][Full Text] [Related]
10. Analysis of HLA class I and II alleles regarding to lymph node and distant metastasis in patients with non-small cell lung cancer.
Bulut I; Meral M; Kaynar H; Pirim I; Bilici M; Gorguner M
Lung Cancer; 2009 Nov; 66(2):231-6. PubMed ID: 19246116
[TBL] [Abstract][Full Text] [Related]
11. Intravascular presence of tumor cells as prognostic parameter in uveal melanoma: a 35-year survey.
Ly LV; Odish OF; Wolff-Rouendaal Dd; Missotten GS; Luyten GP; Jager MJ
Invest Ophthalmol Vis Sci; 2010 Feb; 51(2):658-65. PubMed ID: 19797220
[TBL] [Abstract][Full Text] [Related]
12. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
Kageshita T; Ishihara T; Campoli M; Ferrone S
Tissue Antigens; 2005 May; 65(5):419-28. PubMed ID: 15853896
[TBL] [Abstract][Full Text] [Related]
13. Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population.
Bergman L; Nilsson B; Lundell G; Lundell M; Seregard S
Ophthalmology; 2005 May; 112(5):834-40. PubMed ID: 15878063
[TBL] [Abstract][Full Text] [Related]
14. Pigmented episcleral deposits after brachytherapy of uveal melanoma.
Toivonen P; Kivelä T
Ophthalmology; 2006 May; 113(5):865-73. PubMed ID: 16530837
[TBL] [Abstract][Full Text] [Related]
15. HLA class I and class II genotyping in patients with chronic urticaria.
Coban M; Erdem T; Ozdemir S; Pirim I; Atasoy M; Ikbal M
Int Arch Allergy Immunol; 2008; 147(2):135-9. PubMed ID: 18520158
[TBL] [Abstract][Full Text] [Related]
16. Long-term survival in choroidal and ciliary body melanoma after enucleation versus plaque radiation therapy.
Augsburger JJ; Corrêa ZM; Freire J; Brady LW
Ophthalmology; 1998 Sep; 105(9):1670-8. PubMed ID: 9754176
[TBL] [Abstract][Full Text] [Related]
17. Characterization of melanocortin-1 receptor gene variants in uveal melanoma patients.
Metzelaar-Blok JA; ter Huurne JA; Hurks HM; Keunen JE; Jager MJ; Gruis NA
Invest Ophthalmol Vis Sci; 2001 Aug; 42(9):1951-4. PubMed ID: 11481256
[TBL] [Abstract][Full Text] [Related]
18. Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas.
Kaiserman N; Kaiserman I; Hendler K; Frenkel S; Pe'er J
Br J Ophthalmol; 2009 Sep; 93(9):1167-71. PubMed ID: 19570767
[TBL] [Abstract][Full Text] [Related]
19. Elevated blood β-2 microglobulin is associated with tumor monosomy-3 in patients with primary uveal melanoma.
Triozzi PL; Elson P; Aldrich W; Achberger S; Tubbs R; Biscotti CV; Singh AD
Melanoma Res; 2013 Feb; 23(1):1-7. PubMed ID: 23196330
[TBL] [Abstract][Full Text] [Related]
20. A study of HLA-G polymorphism and linkage disequilibrium in renal transplant patients and their donors.
Pirri A; Contieri FC; Benvenutti R; Bicalho Mda G
Transpl Immunol; 2009 Jan; 20(3):143-9. PubMed ID: 18926911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
